Colon Cancer Clinical Trials and Other Research
Early drug development specialist Dr. Rona Yaeger led research on using the targeted therapy drug adagrasib along with the drug cetuximab to treat advanced colorectal cancer caused by a gene mutation.
The page presents an overview of ongoing and open colon cancer clinical trials at Memorial Sloan Kettering Cancer Center, detailing trial types, locations, and specific research areas—including targeted therapy with adagrasib and cetuximab for advanced disease with gene mutations, and immunotherapy for KRAS/NRAS–driven cancers.
Clinical trials are essential for developing new, more effective treatments and for providing patients with early access to cutting‑edge therapies that may improve outcomes and quality of life.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics